title: Drug inhibitors of RNA polymerase II transcription.
abstract: Transcription by RNA polymerase II occurs after formation of a transcription complex. This complex is assembled in stages by the interaction of transcription factors with the template and/or with each other. We report on the ability of six drugs to inhibit the assembly of the RNA polymerase II transcription complex. Assembly of the complex on the adenovirus major late promoter requires several transcription factors. The normal assembly process requires that the DNA first interact with TFIIA, then with TFIID, and finally with at least four additional transcription factors (one of which is RNA polymerase II). We observed that streptolydigin (10 micrograms/ml) inhibits association of ILA and IID, and at higher concentrations (100 micrograms/ml) inhibits that IIA/IID complex from binding to DNA. Streptovaricin (100 micrograms/ml) appears to inhibit the IIA/IID interaction with DNA and prevents reinitiation (at 500 micrograms/ml). Adriamycin (1 microgram/ml) inhibits the interaction of TFIID with the IIA/DNA complex and inhibits an additional event immediately prior to, or during, elongation. Daunorubicin may be an elongation inhibitor. Heparin at 10 micrograms/ml inhibits further assembly after the IIA/IID/DNA complex has formed, and at 100 micrograms/ml also inhibits a late event in the assembly process and blocks reinitiation. Rifamycin AF/013 (100 micrograms/ml) inhibits the early events necessary to form the IIA/IID/DNA complex and (at 10 micrograms/ml) an assembly event following formation of the IIA/IID/DNA complex. Therefore, these compounds should be useful as probes for further examination of the assembly process.
authors.affiliation: Biology Department, University of Massachusetts, Boston 02125.
authors.forename: K
authors.initials: K
authors.lastname: Logan
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: E A
authors.initials: EA
authors.lastname: Davis
authors.forename: S
authors.initials: S
authors.lastname: Ackerman
mesh_terms: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D006367:HeLa Cells; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D012319:RNA Polymerase II / Q000235:genetics*; D012294:Rifamycins / Q000494:pharmacology; D013310:Streptovaricin / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D012294:Rifamycins; D013310:Streptovaricin; C100307:streptolydigin; D004317:Doxorubicin; D006493:Heparin; D012319:RNA Polymerase II; D003630:Daunorubicin